RxDoctor Payments Data

Safia Abdillahi

Nurse Practitioner · Washington, DCNPI 1881788966

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,975 of the $10,762 with a category attached, or 74.1%. 21 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 25.7% of the total. Among nurse practitioner clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,762in general payments, 2019–2025

Across 359 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$3K
  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • MDD US Operations, LLC$798
  • Neurocrine Biosciences, Inc.$678
  • Kyowa Kirin, Inc.$588
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$2,76326%
  • Food & beverage$7,97574%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,762 in reported general payments places this provider in the 95th percentile of 224 nurse practitioner providers in District of Columbia.

See all nurse practitioner providers in District of Columbia

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl31$145,850
RytaryCarbidopa/Levodopa79$88,403
NuplazidPimavanserin Tartrate11$54,729
OngentysOpicapone19$20,247
NeuproRotigotine23$18,008
Rasagiline Mesylate46$9,860
Carbidopa-LevodopaCarbidopa/Levodopa208$7,271
Pramipexole ErPramipexole Di-Hcl22$6,844
Entacapone15$2,472
Galantamine ErGalantamine Hbr14$2,414
Carbidopa-Levodopa ErCarbidopa/Levodopa24$1,577
Donepezil Hcl65$948
AmantadineAmantadine Hcl12$909
Memantine Hcl32$672
Primidone15$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$798$145,85031 claims
Amneal Pharmaceuticals LLCRytary$2,769$88,40379 claims
Acadia Pharmaceuticals IncNuplazid$1,241$54,72911 claims
Neurocrine Biosciences, Inc.Ongentys$678$20,24719 claims
UCB, Inc.Neupro$25$18,00823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 nurse practitioner providers in District of Columbia.

Other nurse practitioner in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →